Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-ICD: Empagliflozin vs Placebo for Prevention of Lethal Ventricular Arrhythmia in Type 2 Diabetes Patients with ICD
jRCTs031180120Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and ventricular arrhythmia (VA) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoint: frequency of lethal ventricular arrhythmia in implantable cardioverter-defibrillator. Started Apr 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)ventricular arrhythmia (VA)
Beyond the preview
Go deeper on jRCTs031180120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180120.